| Q38092989 | A canine model of human aging and Alzheimer's disease |
| Q47368185 | ABC Transporters Are Key Players in Alzheimer's Disease |
| Q34052308 | ACAT inhibition and amyloid beta reduction |
| Q38172335 | Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease |
| Q28284530 | Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells |
| Q37578762 | Alpha7 nicotinic acetylcholine receptor is required for amyloid pathology in brain endothelial cells induced by Glycoprotein 120, methamphetamine and nicotine |
| Q36535484 | Alzheimer disease and platelets: how's that relevant |
| Q37422795 | Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future |
| Q37145570 | Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease |
| Q39437881 | Amyloid beta: structure, biology and structure-based therapeutic development |
| Q45776839 | Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging |
| Q90405196 | Amyloid-Beta 1-42 Cross-Reactive Antibody Prevalent in Human Sera May Contribute to Intraneuronal Deposition of A-Beta-P-42 |
| Q35183396 | Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent |
| Q28486187 | Amyloid-β peptide on sialyl-Lewis(X)-selectin-mediated membrane tether mechanics at the cerebral endothelial cell surface |
| Q89078262 | An optimized method for enrichment of whole brain-derived extracellular vesicles reveals insight into neurodegenerative processes in a mouse model of Alzheimer's disease |
| Q33839260 | Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta Peptide |
| Q37124428 | Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease |
| Q35909532 | Automated Protein Localization of Blood Brain Barrier Vasculature in Brightfield IHC Images |
| Q30483111 | B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice |
| Q27318080 | Blood platelets in the progression of Alzheimer's disease |
| Q58729492 | Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines |
| Q50778486 | Blood-brain barrier P-glycoprotein function in Alzheimer's disease. |
| Q24631720 | Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease |
| Q47584093 | Blood-derived amyloid-β protein induces Alzheimer's disease pathologies. |
| Q33614467 | Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals |
| Q36221514 | C-Reactive Protein, Advanced Glycation End Products, and Their Receptor in Type 2 Diabetic, Elderly Patients with Mild Cognitive Impairment |
| Q34905120 | Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases |
| Q38879090 | Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease |
| Q35700985 | Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles |
| Q38931182 | Chronic depletion of gonadal testosterone leads to blood-brain barrier dysfunction and inflammation in male mice. |
| Q34960461 | Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease |
| Q52649907 | Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer's disease. |
| Q37165703 | Current and future therapy in Alzheimer's disease. |
| Q37827489 | Current perspectives on pharmacotherapy of Alzheimer's disease |
| Q35394390 | Dementia and Alzheimer's disease: a new direction.The 2010 Jay L. Foster Memorial Lecture |
| Q41383829 | Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice |
| Q37662438 | Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. |
| Q36097397 | Differential accumulation of secreted AbetaPP metabolites in ocular fluids |
| Q53481618 | Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer's Disease. |
| Q27331411 | Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele |
| Q39987132 | Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. |
| Q37402339 | Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance |
| Q38937588 | EGb761 provides a protective effect against Aβ1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model |
| Q64230377 | Effects and Underlying Mechanisms of Bioactive Compounds on Type 2 Diabetes Mellitus and Alzheimer's Disease |
| Q54257701 | Effects of Amyloid Beta Peptide on Neurovascular Cells. |
| Q35912821 | Effects of ethanol on aggregation, serotonin release, and amyloid precursor protein processing in rat and human platelets |
| Q42268833 | Effects of long-term moderate ethanol and cholesterol on cognition, cholinergic neurons, inflammation, and vascular impairment in rats |
| Q42290598 | Endoplasmic Reticulum Malfunction in the Nervous System |
| Q37515497 | Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease |
| Q37383180 | Eradication of Helicobacter pylori Is Associated with the Progression of Dementia: A Population-Based Study |
| Q34342260 | Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer |
| Q37365919 | Evidence of angiogenic vessels in Alzheimer's disease |
| Q89746353 | Extracellular vesicle-mediated amyloid transfer to neural progenitor cells: implications for RAGE and HIV infection |
| Q36812442 | Extracellular vesicles of the blood-brain barrier |
| Q40389352 | Extracellular vesicles of the blood-brain barrier: Role in the HIV-1 associated amyloid beta pathology. |
| Q50239472 | Focused ultrasound as a novel strategy for Alzheimer disease therapeutics |
| Q39847727 | Gelsolin restores A beta-induced alterations in choroid plexus epithelium. |
| Q46113901 | Genetic Association of HLA Gene Variants with MRI Brain Structure in Alzheimer's Disease |
| Q33604503 | HIV-1 stimulates nuclear entry of amyloid beta via dynamin dependent EEA1 and TGF-β/Smad signaling |
| Q39769825 | HIV-1-induced amyloid beta accumulation in brain endothelial cells is attenuated by simvastatin |
| Q36977898 | Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease |
| Q89642624 | Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina |
| Q41209061 | Immunohistochemical detection of receptor-associated protein in normal human brain and Alzheimer's disease |
| Q28269188 | Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitus |
| Q34110934 | Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease |
| Q38447377 | In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer's disease by molecula |
| Q43224146 | Inherited real risk of Alzheimer's disease: bedside diagnosis and primary prevention |
| Q37253971 | Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta} |
| Q21131068 | Interactions of metals and Apolipoprotein E in Alzheimer's disease |
| Q57967107 | Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease |
| Q26745369 | Intracerebral haemorrhage in Down syndrome: protected or predisposed? |
| Q30650803 | Involvement of brain oxidation in the cognitive impairment in a triple transgenic mouse model of Alzheimer's disease: noninvasive measurement of the brain redox state by magnetic resonance imaging. |
| Q43074615 | Kaolin-induced chronic hydrocephalus accelerates amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP. |
| Q37611858 | LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's Disease in humans in-vivo |
| Q34963305 | Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. |
| Q34308819 | Late onset Alzheimer’s disease in older people |
| Q92403076 | Liver Dysfunction as a Novel Player in Alzheimer's Progression: Looking Outside the Brain |
| Q24626770 | Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance |
| Q35020981 | Low-density lipoprotein receptor-related protein is decreased in optic neuropathy of Alzheimer disease |
| Q37215837 | Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease |
| Q37478957 | Metabolic Dysfunction of Astrocyte: An Initiating Factor in Beta-amyloid Pathology? |
| Q38127753 | Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease |
| Q37604174 | Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease. |
| Q34447747 | Mitochondrial DNA Sequence Variation Associated With Peripheral Nerve Function in the Elderly |
| Q37339912 | Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity |
| Q37080236 | Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy |
| Q34277495 | Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease |
| Q37675611 | NETosis in Alzheimer's Disease. |
| Q38358865 | Nanotherapeutic strategies for the treatment of Alzheimer's disease |
| Q35201102 | Neurobiology of the aging dog. |
| Q30054419 | Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease |
| Q35864854 | New insights in the amyloid-Beta interaction with mitochondria |
| Q36876341 | New therapeutic targets in the neurovascular pathway in Alzheimer's disease |
| Q37186246 | Novel technologies for antiangiogenic drug delivery in the brain |
| Q33609310 | Oxidative and pro-inflammatory impact of regular and denicotinized cigarettes on blood brain barrier endothelial cells: is smoking reduced or nicotine-free products really safe? |
| Q34376145 | PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation. |
| Q26777643 | Pathobiology of tobacco smoking and neurovascular disorders: untied strings and alternative products |
| Q98288728 | Pathological Mechanisms Linking Diabetes Mellitus and Alzheimer's Disease: the Receptor for Advanced Glycation End Products (RAGE) |
| Q24627871 | Pathophysiological impact of cigarette smoke exposure on the cerebrovascular system with a focus on the blood-brain barrier: expanding the awareness of smoking toxicity in an underappreciated area |
| Q38313097 | Perlecan domain V inhibits amyloid-β induced brain endothelial cell toxicity and restores angiogenic function |
| Q30439286 | Permeability assessment of the focused ultrasound-induced blood–brain barrier opening using dynamic contrast-enhanced MRI |
| Q48715103 | Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3-induced outside-in signaling and clusterin release |
| Q37670716 | Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges |
| Q37752606 | Proposed mechanism for lipoprotein remodelling in the brain. |
| Q34043168 | Protection after stroke: cellular effectors of neurovascular unit integrity. |
| Q90591155 | Protein transmission in neurodegenerative disease |
| Q23921585 | Protracted exposure to supraphysiological levels of corticosterone does not cause neuronal loss or damage and protects against kainic acid-induced neurotoxicity in the hippocampus of C57BL/6J mice |
| Q36237665 | Quercetin protects human brain microvascular endothelial cells from fibrillar β-amyloid1-40-induced toxicity |
| Q37599419 | RAGE: the beneficial and deleterious effects by diverse mechanisms of actions |
| Q37259863 | Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases |
| Q37560084 | Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease |
| Q34974412 | Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments |
| Q39462209 | Role of Aβ-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A₂ activation in astrocytes and cerebral endothelial cells. |
| Q41835365 | Role of Notch-1 signaling pathway in PC12 cell apoptosis induced by amyloid beta-peptide (25-35) |
| Q39057175 | Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
| Q35810686 | Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro |
| Q37317769 | Simvastatin protects against amyloid beta and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells |
| Q37844327 | Sink hypothesis and therapeutic strategies for attenuating Abeta levels |
| Q50880511 | Soluble aggregates of the amyloid-beta protein activate endothelial monolayers for adhesion and subsequent transmigration of monocyte cells. |
| Q38610113 | Strategies to target drugs to gliomas and CNS metastases of solid tumors |
| Q38589876 | TRAF6 and p62 inhibit amyloid β-induced neuronal death through p75 neurotrophin receptor |
| Q38674279 | Targeting specific cells in the brain with nanomedicines for CNS therapies |
| Q41980641 | The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction |
| Q28084591 | The Glymphatic System: A Beginner's Guide |
| Q38899745 | The blood-brain barrier in Alzheimer's disease. |
| Q37385549 | The blood-brain barrier in neurodegenerative disease: a rhetorical perspective |
| Q48951906 | The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells |
| Q46972864 | The road to LOAD: late-onset Alzheimer's disease and a possible way to block it. |
| Q35551001 | The role of environmental exposures in neurodegeneration and neurodegenerative diseases |
| Q36841789 | The role of microglia in amyloid clearance from the AD brain |
| Q37232866 | The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease |
| Q64990947 | The troubling story of blood-driven dementias. |
| Q33584889 | The use of recently developed histochemical markers for localizing neurotoxicant induced regional brain pathologies |
| Q48017362 | The vascular basement membrane in the healthy and pathological brain. |
| Q35748045 | Tissue-engineered microenvironment systems for modeling human vasculature |
| Q39906493 | Tong Luo Jiu Nao, a Chinese Medicine Formula, Reduces Inflammatory Stress in a Mouse Model of Alzheimer's Disease |
| Q35072502 | Transcriptional profile of HIV-induced nuclear translocation of amyloid β in brain endothelial cells |
| Q28729033 | Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models |
| Q34680483 | Vascular basis for brain degeneration: faltering controls and risk factors for dementia |
| Q35866844 | Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet |
| Q33780717 | Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins |
| Q39987921 | Vascular insufficiency, not inflammation, contributes to chronic gliosis in a rat CNS transplantation model |
| Q50879881 | Vascular senescence and ageing: a role for the MEOX proteins in promoting endothelial dysfunction. |
| Q33739902 | Viable mouse gene ablations that robustly alter brain Aβ levels are rare |
| Q52597873 | β-Amyloid accumulation in the human brain after one night of sleep deprivation. |
| Q47705574 | β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling |